PHENOTYPE LOCK
Live / Applied — Third extension granted (statement of use) (as of 23 Oct 2025)
What this means for you
Not registered yet, but its 29 Apr 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97388990
- Mark type
- Stylized text
- Filed
- 29 Apr 2022
- Published for opposition
- 19 Mar 2024
- Attorney of record
- Carlynn Beth Ferguson
Goods and services
- Class 001 — Chemicals: Chemical and biological preparations for use in science and industry; Chemical and biological preparations for genetically modifying human and animal cells for non-medical purposes; reagents for use in the genetic modification of human and animal cells for scientific or medical research use; human and animal cells and parts in the nature of stem cells thereof for scientific and research purposes; T cells for scientific and research purposes; regulatory T cells for scientific and research purposes; preparations of blood or cells extracted from humans and animals for scientific and research purposes; chimeric antigen receptors and preparations thereof for scientific and research purposes; antibody reagents used for the detection of antigens in cell and tissue analysis for in vitro diagnostic use for use in science and industry; nucleic acids for laboratory use; synthetic deoxyribonucleic acids for scientific purposes; viral vectors for use in science and industry; nucleic acid vectors for use in science and industry
- Class 005 — Pharmaceuticals: Pharmaceutical and biological preparations for diagnostic, medical, therapeutic and prophylactic use, namely for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; pharmaceutical, medical and veterinary preparations for diagnostic, therapeutic and prophylactic purposes, namely for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; pharmaceutical preparations for cell therapy; pharmaceutical preparations for gene therapy; pharmaceutical preparations for genetically modifying human and animal cells for diagnostic and medical purposes; human and animal cells and parts, namely stem cells thereof for medical and veterinary purposes; T cells for medical and veterinary purposes; regulatory T cells for medical and veterinary purposes; preparations of blood or cells extracted from humans and animals which have been adapted for therapeutic purposes; pharmaceutical, medical and clinical preparations for use in treatment, amelioration and prophylaxis of diseases, disorders and suppression of the immune system; immunological agents and preparations for medical purposes, namely for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; pharmaceutical preparations for therapies to modulate the immune system; pharmaceutical preparations for therapies for autoimmune conditions and immunological disorders; chimeric antigen receptors and therapeutic preparations for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; pharmaceutical preparations for therapeutic delivery of nucleic acids; viral vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; nucleic acid vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; medical pharmaceutical preparations containing viral vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; medical preparations containing nucleic acid vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection
- Class 040 — Treatment of materials: Pharmaceutical manufacturing and processing; biological, biotechnological and biopharmaceutical manufacturing and manufacturing processing; manufacturing processing of biological tissue, blood, cell and genetic material; viral vector production, namely manufacture; gene therapy production, namely manufacture; custom manufacture of pharmaceutical and biological formulations and products; processing and modification of human and animal cells in the custom manufacture of pharmaceutical and biological formulations and products
Owner
- Quell Therapeutics Limited, London, GB
- Quell Therapeutics Limited, London, GB
Prosecution history
- 23 Oct 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 23 Oct 2025 — SOU EXTENSION 3 GRANTED
- 23 Oct 2025 — SOU EXTENSION 3 FILED
- 23 Oct 2025 — SOU TEAS EXTENSION RECEIVED
- 22 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 21 Mar 2025 — SOU EXTENSION 2 GRANTED
- 21 Mar 2025 — SOU EXTENSION 2 FILED
- 21 Mar 2025 — SOU TEAS EXTENSION RECEIVED
- 13 Jun 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 05 Jun 2024 — SOU EXTENSION 1 GRANTED
- 05 Jun 2024 — SOU EXTENSION 1 FILED
- 05 Jun 2024 — SOU TEAS EXTENSION RECEIVED
- 14 May 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 19 Mar 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 19 Mar 2024 — PUBLISHED FOR OPPOSITION